Jazz Pharmaceuticals (JAZZ) Stock Forecast & Price Target

$120.42

+0.87 (+0.73%)

(As of 12/8/2023 ET)

Today's Range: $119.52
▼
$121.64
50-Day Range: $114.26
▼
$136.00
52-Week Range: $111.25
▼
$160.96

Volume: 504,145 shs
Average Volume: 564,180 shs
Market Capitalization: $7.58 billion

P/E Ratio: 136.84
Dividend Yield: N/A
Price Target: $195.50

Jazz Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 9 Analyst Ratings

Analysts' Consensus Price Target

$195.50
62.35% Upside

High Forecast	$225.00
Average Forecast	$195.50
Low Forecast	$135.00

Type	Current Forecast 12/8/22 to 12/8/23	1 Month Ago 11/8/22 to 11/8/23	3 Months Ago 9/9/22 to 9/9/23	1 Year Ago 12/8/21 to 12/8/22
Consensus Rating	Moderate Buy	Moderate Buy	Buy	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	6 Buy rating(s)	6 Buy rating(s)	9 Buy rating(s)
Hold	2 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$195.50	$206.67	$206.67	$202.33
Predicted Upside	62.35% Upside	50.64% Upside	50.64% Upside	34.29% Upside

Get Jazz Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for JAZZ and its competitors with MarketBeat's FREE daily newsletter.

JAZZ Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

JAZZ Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Jazz Pharmaceuticals Stock vs. The Competition

Type	Jazz Pharmaceuticals	Medical Companies	S&P 500
Consensus Rating Score	2.78	2.68	2.49
Consensus Rating	Moderate Buy	Moderate Buy	Hold
Predicted Upside	62.35% Upside	728.30% Upside	3,819.06% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Ratings and Stock Forecasts

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/4/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$200.00	+64.20%
11/29/2023	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$225.00	+96.52%
11/27/2023	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$170.00 ➝ $135.00	+11.25%
11/9/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$200.00 ➝ $191.00	+63.92%
9/28/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
8/22/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Duncan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$180.00	+28.43%
8/11/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$204.00	+50.91%
8/10/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$204.00 ➝ $217.00	+60.74%
3/3/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$190.00 ➝ $212.00	+45.30%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 10:27 PM ET.

JAZZ Price Target - Frequently Asked Questions

What is Jazz Pharmaceuticals's consensus rating and price target?: According to the issued ratings of 9 analysts in the last year, the consensus rating for Jazz Pharmaceuticals stock is Moderate Buy based on the current 2 hold ratings and 7 buy ratings for JAZZ. The average twelve-month price prediction for Jazz Pharmaceuticals is $195.50 with a high price target of $225.00 and a low price target of $135.00. Learn more on JAZZ's analyst rating history.
Do Wall Street analysts like Jazz Pharmaceuticals more than its competitors?: Analysts like Jazz Pharmaceuticals more than other Medical companies. The consensus rating score for Jazz Pharmaceuticals is 2.78 while the average consensus rating score for medical companies is 2.68. Learn more on how JAZZ compares to other companies.
Is Jazz Pharmaceuticals being downgraded by Wall Street analysts?: Over the previous 90 days, Jazz Pharmaceuticals's stock had 1 downgrade by analysts.

Does Jazz Pharmaceuticals's stock price have much upside?: According to analysts, Jazz Pharmaceuticals's stock has a predicted upside of 51.79% based on their 12-month stock forecasts.
What analysts cover Jazz Pharmaceuticals?: Jazz Pharmaceuticals has been rated by Needham & Company LLC, Raymond James, Royal Bank of Canada, Truist Financial, and UBS Group in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:JAZZ) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial